Overview
KINDSTAR GLOBAL (9960)
Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People’s Republic of China and Mainland China. It...
- Open
- 0.895
- High
- 0.895
- Low
- 0.860
- Prev. Close
- 0.875
- Volume
- 229.00K
- Turnover
- 201.95K
- Avg Price
- 0.882
- Bid/Ask Ratio
- -77.78%
- Amplitude
- 4.00%
- 52wk High
- 1.205
- Volume Ratio
- 0.53
- Turnover Ratio
- 0.02%
- 52wk Low
- 0.855
- HK Mkt Cap
- 923.09M
- Market CapHKD
- 923.09M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.0464
- EPSDynamic
- -0.0421
- EPSStatic
- --
- BVPS
- 2.88
- P/B
- 0.31
- HK Shares
- 1.03B
- Dividend YieldTTM
- 10.64%
- DividendTTM
- 0.095
- Shares
- 1.03B
- Min lot size
- 500
- Currency
- HKD
KINDSTAR GLOBAL Analyst Rating
View moreForecast & Rating
Oct 7, 2024- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Kindstar Global (9960.HK) closed up 2.3% at HK$0.895, with the stock having touched a 52-week low of HK$0.855 this week; an afternoon dip to HK$0.860 drew bids and the shares were pulled back to the session high by the close in a V-shaped recovery on just 220,000 shares and HK$193,890 of turnover, a 0.02% turnover rate. The session coincided with a run of HKEX next-day disclosure returns on share buybacks, one at an average price of about HK$0.94. Q2 2026 revenue rose 9.26% y/y to HK$273.5m and the net loss narrowed 44.88% to HK$10.9m, yet EPS stays at -HK$0.0109 with PE of -19.3 and PB of 0.31. The price is back above MA20 of 0.892 but still under MA60 of 0.919, down 23.5% year to date and 32.2% below the HK$1.32 52-week high, with the death cross intact. Though the bounce rests on very thin turnover.
- Oct, 27
Kindstar Globalgene (9960.HK) fell about 3.9% to HK$0.865, printing a fresh 52-week low of HK$0.855 at 10:14 BJ on 136,000 shares traded. Buybacks have been near-daily through October, including 5,000 shares for HK$4,502.5 on Oct 26, yet against a market capitalisation of roughly HK$892 million the support has been limited. Q2 2026 revenue rose 9.26% year on year to HK$273.5 million while the net loss narrowed 44.88% to HK$10.89 million, leaving the net margin at -3.98% and price-to-book near 0.30. The shares are down 26.07% year to date, 38.65% below the 52-week high of HK$1.41, and trade under both the MA20 of 0.912 and the MA60 of 0.933. Though the roughly 45% narrowing in losses and two consecutive quarters of about 9% revenue growth remain the counterpoint to the weak price action.
- Oct, 14
Kindstar Globalgene (9960.HK) reversed early gains and drifted lower, opening flat at HK$0.935 and closing at HK$0.900, down 3.74%, after touching HK$0.895 intraday on thin volume of 781,500 shares worth about HK$0.71m. The close sits below MA20 of HK$0.923 and MA60 of HK$0.941, with the stock down 23.08% year-to-date and 42.31% below its 52-week high of HK$1.56, while the HK$0.895 low matched the prior session's 52-week trough. The latest quarter shows narrowing losses rather than growth: Q2 2026 revenue rose 9.26% year-on-year to HK$273.5m, the net loss of HK$10.9m contracted 44.88% and EPS of -HK$0.0109 improved 47.25%, leaving net margin at -3.98%. Near-daily buybacks since mid-September, including 18,000 shares for HK$16,700 on 13 October and 24,000 shares on 8 October, failed to hold intraday prices, though turnover of just 0.08% suggests sparse trading magnified the decline.
- Sep, 3
Kindstar Globalgene traded flat at HK$1.00 during the morning session, recovering from an intraday low of HK$0.980, with a daily range of about 2%. The stock was supported by the company's ongoing share buyback and cancellation activities, as evidenced by multiple recent HKEX filings, coupled with the FY26 H1 results released last night showing a 44.7% narrowing of net loss to RMB 18.1 million, while revenue grew 3.7% to RMB 473.6 million. The current price is 35.9% below the 52-week high of HK$1.56 but has reclaimed both the 20-day MA (HK$0.956) and 60-day MA (HK$0.965), though the year-to-date decline stands at 14.53%. However, the company remains loss-making with a P/E of -21.59x and a P/B of 0.35x, warranting caution on the sustainability of the turnaround.
- Sep, 1
Kindstar Global closed at HKD 0.995, flat from the previous close, after a session that saw prices dip to HKD 0.970 in the morning before recovering in the afternoon. Frequent share buybacks (e.g., at HKD 0.94-0.99 for cancellation) provided support, while the interim net loss narrowed 44.7% to RMB 18.1 million with revenue up 3.7% to RMB 473.6 million, driven by oncology testing. Despite the improvement, the net profit margin remained negative. The stock trades 41.5% below its 52-week high of HKD 1.71 and below both the MA20 (HKD 0.951) and MA60 (HKD 0.966), indicating a depressed valuation, though YTD it is down 14.5% with thin overall volume of 865,000 shares.
